TY - JOUR
T1 - Radiation therapy for the whole breast
T2 - Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline
AU - Smith, Benjamin D.
AU - Bellon, Jennifer R.
AU - Blitzblau, Rachel
AU - Freedman, Gary
AU - Haffty, Bruce
AU - Hahn, Carol
AU - Halberg, Francine
AU - Hoffman, Karen
AU - Horst, Kathleen
AU - Moran, Jean
AU - Patton, Caroline
AU - Perlmutter, Jane
AU - Warren, Laura
AU - Whelan, Timothy
AU - Wright, Jean L.
AU - Jagsi, Reshma
N1 - Publisher Copyright:
© 2018 American Society for Radiation Oncology
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Introduction: The purpose of this guideline is to offer recommendations on fractionation for whole breast irradiation (WBI) with or without a tumor bed boost and guidance on treatment planning and delivery. Methods and materials: The American Society for Radiation Oncology (ASTRO) convened a task force to address 5 key questions focused on dose-fractionation for WBI, indications and dose-fractionation for tumor bed boost, and treatment planning techniques for WBI and tumor bed boost. Guideline recommendations were based on a systematic literature review and created using a predefined consensus-building methodology supported by ASTRO-approved tools for grading evidence quality and recommendation strength. Results: For women with invasive breast cancer receiving WBI with or without inclusion of the low axilla, the preferred dose-fractionation scheme is hypofractionated WBI to a dose of 4000 cGy in 15 fractions or 4250 cGy in 16 fractions. The guideline discusses factors that might or should affect fractionation decisions. Use of boost should be based on shared decision-making that considers patient, tumor, and treatment factors, and the task force delineates specific subgroups in which it recommends or suggests use or omission of boost, along with dose recommendations. When planning, the volume of breast tissue receiving >105% of the prescription dose should be minimized and the tumor bed contoured with a goal of coverage with at least 95% of the prescription dose. Dose to the heart, contralateral breast, lung, and other normal tissues should be minimized. Conclusions: WBI represents a significant portion of radiation oncology practice, and these recommendations are intended to offer the groundwork for defining evidence-based practice for this common and important modality. This guideline also seeks to promote appropriately individualized, shared decision-making regarding WBI between physicians and patients.
AB - Introduction: The purpose of this guideline is to offer recommendations on fractionation for whole breast irradiation (WBI) with or without a tumor bed boost and guidance on treatment planning and delivery. Methods and materials: The American Society for Radiation Oncology (ASTRO) convened a task force to address 5 key questions focused on dose-fractionation for WBI, indications and dose-fractionation for tumor bed boost, and treatment planning techniques for WBI and tumor bed boost. Guideline recommendations were based on a systematic literature review and created using a predefined consensus-building methodology supported by ASTRO-approved tools for grading evidence quality and recommendation strength. Results: For women with invasive breast cancer receiving WBI with or without inclusion of the low axilla, the preferred dose-fractionation scheme is hypofractionated WBI to a dose of 4000 cGy in 15 fractions or 4250 cGy in 16 fractions. The guideline discusses factors that might or should affect fractionation decisions. Use of boost should be based on shared decision-making that considers patient, tumor, and treatment factors, and the task force delineates specific subgroups in which it recommends or suggests use or omission of boost, along with dose recommendations. When planning, the volume of breast tissue receiving >105% of the prescription dose should be minimized and the tumor bed contoured with a goal of coverage with at least 95% of the prescription dose. Dose to the heart, contralateral breast, lung, and other normal tissues should be minimized. Conclusions: WBI represents a significant portion of radiation oncology practice, and these recommendations are intended to offer the groundwork for defining evidence-based practice for this common and important modality. This guideline also seeks to promote appropriately individualized, shared decision-making regarding WBI between physicians and patients.
UR - http://www.scopus.com/inward/record.url?scp=85043380834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043380834&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2018.01.012
DO - 10.1016/j.prro.2018.01.012
M3 - Article
C2 - 29545124
AN - SCOPUS:85043380834
SN - 1879-8500
VL - 8
SP - 145
EP - 152
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 3
ER -